文献速递炎症性肠病

炎症性肠病缓解期患者停用抗肿瘤坏死因子治疗后的长期结局:GETECCU的EXIT长期研究

Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
PubMed 文献 · Aliment Pharmacol Ther · 2025-05-02

EXIT试验的随访扩展分析纳入125例持续临床缓解的炎症性肠病患者(维持治疗组63例、停药组62例),比较两组长期复发风险及重启抗TNF治疗的应答。维持治疗组与停药组累积复发率分别为35%与47%(p=0.3),基线粪钙卫蛋白>250 μg/g是唯一与复发风险升高相关的变量;停药组复发者90%重启抗TNF治疗,其中69%重获临床缓解。

要点

  • 停药组与维持治疗组累积复发率分别为47%与35%,差异无统计学意义(p=0.3)。
  • 基线粪钙卫蛋白>250 μg/g是唯一与复发风险升高相关的变量。
  • 停药组复发者90%重启抗TNF治疗,69%重获临床缓解。

核心结论

  • 在EXIT试验的扩展分析中,炎症性肠病缓解期患者停用抗TNF治疗与长期复发风险升高无关。

研究设计与样本

  • EXIT试验的随访扩展分析,从EXIT研究起始分析持续临床缓解患者的长期结局。
  • 共纳入125例患者,维持治疗组63例,停药组62例。

主要发现

  • 维持治疗组中位随访12个月,停药组中位随访26个月。
  • 累积复发率(95%CI)维持治疗组为35%(23%-48%),停药组为47%(34%-60%),p=0.3。
  • 维持治疗组12个月时复发8%、24个月时复发47%;停药组12个月时复发16%、24个月时复发39%。
  • 每患者年复发率维持治疗组为22%,停药组为19%。
  • 基线粪钙卫蛋白>250 μg/g是唯一与复发风险升高相关的变量。

关键数值与推荐

  • 停药组29例复发患者中26例(90%)重启抗TNF治疗,其中69%重获临床缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)]. AIMS: To compare the long-term risk of relapse between these groups and assess the response to anti-TNF resumption. METHODS: This was a follow-up extension of the EXIT trial. We analysed long-term outcomes of patients in sustained clinical remission from the start of EXIT. RESULTS: We included 125 patients (63 in MA and 62 in WA). Median follow-up was 12 months for MA and 26 months for WA. The cumulative incidence of relapse (95% CI) was 35% (23%-48%) in MA and 47% (34%-60%) in WA; p = 0.3. In MA, relapses occurred in 8% of patients by 12 months and 47% by 24 months. In WA, relapses occurred in 16% by 12 months and 39% by 24 months. The incidence rate of relapse per patient-year was 22% in MA and 19% in WA. Baseline faecal calprotectin > 250 μg/g was the only variable associated with a higher risk of relapse. Of the 29 patients who relapsed in WA, 26 (90%) resumed anti-TNF therapy; of these, 69% regained clinical remission. CONCLUSION: In this extended analysis of patients included in the EXIT trial, withdrawing anti-TNF therapy in patients with IBD in remission was not associated with a higher long-term relapse risk.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Casanova MJ, Rubín de Célix C, Riestra S, et al. Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU. Aliment Pharmacol Ther. 2025. PMID: 40317957. doi:10.1111/apt.70172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。